Hospital Universitario Virgen de las Nieves-ko ikertzaileekin lankidetzan egindako argitalpenak (15)

2022

  1. Circulating Tumor Cells for the Staging of Patients With Newly Diagnosed Transplant-Eligible Multiple Myeloma

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 40, Núm. 27, pp. 3151-3161

2021

  1. Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard- And high-risk myeloma

    Blood, Vol. 137, Núm. 1, pp. 49-60

  2. Proposed global prognostic score for systemic mastocytosis: a retrospective prognostic modelling study

    The Lancet Haematology, Vol. 8, Núm. 3, pp. e194-e204

2020

  1. Circulating tumor cells for comprehensive and multiregional non-invasive genetic characterization of multiple myeloma

    Leukemia, Vol. 34, Núm. 11, pp. 3007-3018

  2. Immunogenomic identification and characterization of granulocytic myeloid-derived suppressor cells in multiple myeloma

    Blood, Vol. 136, Núm. 2, pp. 199-209

  3. Measurable Residual Disease by Next-Generation Flow Cytometry in Multiple Myeloma

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 38, Núm. 8, pp. 784-792

  4. Transcriptional profiling of circulating tumor cells in multiple myeloma: a new model to understand disease dissemination

    Leukemia, Vol. 34, Núm. 2, pp. 589-603

2018

  1. Next generation flow for minimally-invasive blood characterization of MGUS and multiple myeloma at diagnosis based on circulating tumor plasma cells (CTPC)

    Blood cancer journal, Vol. 8, Núm. 12, pp. 117

2015

  1. Classification and clinical behavior of blastic plasmacytoid dendritic cell neoplasms according to their maturation-associated immunophenotypic profile

    Oncotarget, Vol. 6, Núm. 22, pp. 19204-19216

2012

  1. ANALYSIS OF HLA CLASS I CELL SURFACE EXPRESSION DURING HEMATOPOIETIC DIFFERENTIATION USING THE INFINICYT SOFTWARE

    TISSUE ANTIGENS

  2. Complete response after imatinib mesylate therapy in a patient with well-differentiated systemic mastocytosis

    Journal of Clinical Oncology, Vol. 30, Núm. 12

2008

  1. Evaluation of functional single nucleotide polymorphisms of different genes coding for the immunoregulatory molecules in patients with monoclonal large granular lymphocyte lymphocytosis

    Human Immunology, Vol. 69, Núm. 2, pp. 101-107

  2. Expanded cells in monoclonal TCR-άΒ+/CD4+/NKa+/CD8-/+dim T-LGL lymphocytosis recognize hCMV antigens

    Blood, Vol. 112, Núm. 12, pp. 4609-4616

2007

  1. Monoclonal TCR-Vβ13.1+/CD4+/NKa +/CD8-/+dim T-LGL lymphocytosis: Evidence for an antigen-driven chronic T-cell stimulation origin

    Blood, Vol. 109, Núm. 11, pp. 4890-4898

2004

  1. Incidence and characteristics of CD4+/HLA DRhi dendritic cell malignancies

    Haematologica, Vol. 89, Núm. 1, pp. 58-69